Carvedilol drug in ACLF Patients (liver disease).
Not Applicable
- Conditions
- Health Condition 1: K768- Other specified diseases of liver
- Registration Number
- CTRI/2024/03/064273
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Age 18–70 yrs
2.ACLF diagnosis (AARC criteria)
Exclusion Criteria
1.Contraindications to NSBB (Heart rate less than 65 per min, BP less than 110 by 65 mm Hg, Asthma, Heart failure, AKI, Large ascites, SBP, S. Na less than 125)
2.PVT
3.HCC
4.BCS
5.HE grades 2 to 4
6.NSBB therapy within 5 days
7.Pregnancy
8.Lactation
9.Planned for LT in the next 12 weeks
10.No consent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Predictive value of acute HVPG change by carvedilol for 28 day transplant free survival in patients of ACLFTimepoint: Day 28
- Secondary Outcome Measures
Name Time Method Complications [PHT related bleed, AKI, infections, HE, Hypotension, Cardiac side effect] within 90 daysTimepoint: 90 days;Correlation with evolution of AARC score by 2 weeksTimepoint: 2 weeks;Transplant-free survival rate at 90 daysTimepoint: 90 days